To explore the way of carrying out the risk communication method of "patient safety medication guides" in China.
We reviewed the guidelines and regulations on "patient safety medication guides" issued by the drug regulatory authorities in typical countries, the United States and Japan, and the differences in their production, format content and other aspects were analyzed.
Although both the United States and Japan implement the "patient safety medication guides" work, there are different regulatory requirements in various aspects. In addition, Japan does not have specific requirements for the format of patients safe medication, nor does it elaborate on the specific distribution requirements.
China could appropriately learn from the advanced experience of the United States and Japan, carry out the work of "patient safety medication guides", issue relevant guidelines as soon as possible, and specify the specific production requirements of "patient safety medication guides" in detail.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |